# VHCP Management II, LLC

> Institutional holdings reported to the SEC as of Q4 2019 on Form 13F. CIK 1602263. Source: https://holderbook.com/funds/1602263-vhcp-management-ii-llc/

- Reported value: $379.4M
- Positions: 20
- Weight of the ten largest: 94.1%
- Filed: 2020-02-13

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| 10X GENOMICS INC | [TXG](https://holderbook.com/stocks/TXG/) | $136.2M | 1,786,431 | 35.9% | 2 |
| AXSOME THERAPEUTICS INC | [AXSM](https://holderbook.com/stocks/AXSM/) | $81.2M | 785,981 | 21.4% | 4 |
| CONSTELLATION PHARMCETICLS I | [CNST](https://holderbook.com/stocks/CNST/) | $70.7M | 1,500,631 | 18.6% | 5 |
| BIOHAVEN PHARMACTL HLDG CO L | [BHVNXXXX](https://holderbook.com/stocks/BHVNXXXX/) | $25.2M | 462,903 | 6.6% | 5 |
| SHOCKWAVE MED INC | [SWAV](https://holderbook.com/stocks/SWAV/) | $12.7M | 288,838 | 3.3% | 4 |
| IVERIC BIO INC | [ISEE](https://holderbook.com/stocks/ISEE/) | $8.6M | 1,004,299 | 2.3% | 1 |
| KALVISTA PHARMACEUTICALS INC | [KALV](https://holderbook.com/stocks/KALV/) | $6.5M | 366,268 | 1.7% | 5 |
| OBSEVA SA | [OBSVF](https://holderbook.com/stocks/OBSVF/) | $6.0M | 1,573,639 | 1.6% | 5 |
| MERSANA THERAPEUTICS INC COM | [MRSN](https://holderbook.com/stocks/MRSN/) | $5.3M | 922,514 | 1.4% | 1 |
| SPERO THERAPEUTICS INC | [SPRO](https://holderbook.com/stocks/SPRO/) | $4.6M | 474,015 | 1.2% | 5 |
| RELMADA THERAPEUTICS INC | [RLMD](https://holderbook.com/stocks/RLMD/) | $4.5M | 114,876 | 1.2% | 1 |
| ADVERUM BIOTECHNOLOGIES INC | [ADVM](https://holderbook.com/stocks/ADVM/) | $4.4M | 383,620 | 1.2% | 1 |
| MARINUS PHARMACEUTICALS INC | [MRNS](https://holderbook.com/stocks/MRNS/) | $3.2M | 1,486,676 | 0.8% | 5 |
| FORTY SEVEN INC | [FTSV](https://holderbook.com/stocks/FTSV/) | $3.1M | 77,714 | 0.8% | 1 |
| MILESTONE PHARMACEUTICALS IN | [MIST](https://holderbook.com/stocks/MIST/) | $2.4M | 148,560 | 0.6% | 3 |
| NEXTCURE INC | [NXTC](https://holderbook.com/stocks/NXTC/) | $2.0M | 36,249 | 0.5% | 1 |
| MYOVANT SCIENCES LTD | [MYOV](https://holderbook.com/stocks/MYOV/) | $1.2M | 76,768 | 0.3% | 1 |
| 89BIO INC | [ETNB](https://holderbook.com/stocks/ETNB/) | $1.1M | 41,235 | 0.3% | 1 |
| BELLEROPHON THERAPEUTICS INC | [BLPH](https://holderbook.com/stocks/BLPH/) | $230.0K | 659,087 | 0.1% | 5 |
| PROTAGONIST THERAPEUTICS INC | [PTGX](https://holderbook.com/stocks/PTGX/) | $227.0K | 32,211 | 0.1% | 5 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q4 2019 | +70.5% | +8.5% | +62.0% | 100% |
| Q3 2019 | -24.2% | +1.3% | -25.5% | 100% |
| Q2 2019 | -1.4% | +3.7% | -5.1% | 100% |
| Q1 2019 | +35.2% | +13.0% | +22.2% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q4 2019 | $379.4M | 20 |
| Q3 2019 | $262.4M | 21 |
| Q2 2019 | $317.2M | 21 |
| Q1 2019 | $341.8M | 21 |
| Q4 2018 | $233.0M | 19 |